343 related articles for article (PubMed ID: 19335931)
1. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
Leucht S; Kissling W; Davis JM
Psychol Med; 2009 Oct; 39(10):1591-602. PubMed ID: 19335931
[TBL] [Abstract][Full Text] [Related]
2. What do large scale studies of medication in schizophrenia add to our management strategies?
Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic safety and efficacy concerns.
Meyer JM
J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
6. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
Volavka J; Citrome L
Expert Opin Pharmacother; 2009 Aug; 10(12):1917-28. PubMed ID: 19558339
[TBL] [Abstract][Full Text] [Related]
7. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
Naber D; Lambert M
CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
[TBL] [Abstract][Full Text] [Related]
8. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
9. The CATIE schizophrenia trial: results, impact, controversy.
Manschreck TC; Boshes RA
Harv Rev Psychiatry; 2007; 15(5):245-58. PubMed ID: 17924259
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of the efficacy of second-generation antipsychotics.
Davis JM; Chen N; Glick ID
Arch Gen Psychiatry; 2003 Jun; 60(6):553-64. PubMed ID: 12796218
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.
Foussias G; Remington G
Can J Psychiatry; 2010 Mar; 55(3):117-25. PubMed ID: 20370961
[TBL] [Abstract][Full Text] [Related]
12. First- and second-generation antipsychotics: learning from CUtLASS and CATIE.
Tandon R; Carpenter WT; Davis JM
Arch Gen Psychiatry; 2007 Aug; 64(8):977-8; author reply 979-80. PubMed ID: 17679642
[No Abstract] [Full Text] [Related]
13. New generation vs. first generation antipsychotics debate: pragmatic clinical trials and practice-based evidence.
Jakovljević M
Psychiatr Danub; 2009 Dec; 21(4):446-52. PubMed ID: 19935477
[TBL] [Abstract][Full Text] [Related]
14. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems.
Hamann J; Leucht S; Kissling W
Pharmacopsychiatry; 2003 Jan; 36(1):18-26. PubMed ID: 12649770
[TBL] [Abstract][Full Text] [Related]
15. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder.
Gentile S
J Clin Psychopharmacol; 2007 Feb; 27(1):35-45. PubMed ID: 17224710
[TBL] [Abstract][Full Text] [Related]
16. Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other.
Fleischhacker WW; Widschwendter CG
Curr Opin Psychiatry; 2006 Mar; 19(2):128-34. PubMed ID: 16612191
[TBL] [Abstract][Full Text] [Related]
17. Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?
Motlová L; Spaniel F; Höschl C; Balon R
Ann Clin Psychiatry; 2007; 19(2):133-43. PubMed ID: 17612853
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
Lieberman JA
Arch Gen Psychiatry; 2006 Oct; 63(10):1069-72. PubMed ID: 17015808
[No Abstract] [Full Text] [Related]
19. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial.
Weiden PJ
J Clin Psychiatry; 2007; 68 Suppl 1():12-9. PubMed ID: 17286523
[TBL] [Abstract][Full Text] [Related]
20. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects.
Conley RR; Kelly DL
Isr J Psychiatry Relat Sci; 2005; 42(1):51-60. PubMed ID: 16134407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
